ArticleInvestigational new drugs2023

A tumor-selective adenoviral vector platform induces transient antiphospholipid antibodies, without increased risk of thrombosis, in phase 1 clinical studies.

Danny N Khalil et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.